Neoplasm of mature B-cells
MONDO:0004949A neoplasm of follicle center B cells which has at least a partial follicular pattern. Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)]. Histological grade correlates with prognosis. Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).
Also known as: mature B-cell lymphocytic neoplasm, mature B-cell neoplasm, mature B-cell neoplasms
4505 clinical trials for this condition and its sub-types, 14 tagged with Neoplasm of mature B-cells itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Neoplasm of mature B-cells
-
Plasma cell neoplasm 107 trials · 1,148 incl. sub-types
7 sub-types
- Plasma cell myeloma 1,105 trials · 1,128 incl. sub-types Sub-types →
- Refractory plasma cell neoplasm 228 trials
- Plasma cell leukemia 32 trials
- Plasmacytoma 9 trials · 17 incl. sub-types Sub-types →
- Non-amyloid monoclonal immunoglobulin deposition disease 3 trials · 11 incl. sub-types Sub-types →
- Heavy chain disease 1 trial · 2 incl. sub-types Sub-types →
- Leukemoid reaction 0 trials
-
Diffuse large B-cell lymphoma 632 trials · 754 incl. sub-types
30 sub-types
- Relapsed/refractory diffuse large B-cell lymphoma 210 trials
- High grade B-cell lymphoma 184 trials
- Primary mediastinal large B-cell lymphoma 175 trials
- T-cell/histiocyte rich large B cell lymphoma 31 trials
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly 23 trials
- Diffuse large B-cell lymphoma of the central nervous system 21 trials
- Plasmablastic lymphoma 20 trials
- Primary effusion lymphoma 18 trials
- Diffuse large B-cell lymphoma germinal center B-cell type 13 trials
- Diffuse large B-cell lymphoma activated B-cell type 9 trials
- Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types Sub-types →
- Primary cutaneous diffuse large B-cell lymphoma, Leg type 7 trials
- ALK-positive large B-cell lymphoma 5 trials
- Intravascular large B-cell lymphoma 4 trials
- Diffuse large B-cell lymphoma with chronic inflammation 3 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- EZB diffuse large B-cell lymphoma 0 trials · 2 incl. sub-types Sub-types →
- MCD diffuse large B-cell lymphoma 1 trial
- Breast diffuse large B-cell lymphoma 1 trial
- A53 diffuse large B-cell lymphoma 0 trials
- BN2 diffuse large B-cell lymphoma 0 trials
- N1 diffuse large B-cell lymphoma 0 trials
- ST2 diffuse large B-cell lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric diffuse large B-cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Splenic diffuse large B-cell lymphoma 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Follicular lymphoma 590 trials
-
B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types
2 sub-types
- Chronic lymphocytic leukemia/small lymphocytic lymphoma 107 trials · 108 incl. sub-types Sub-types →
- Hairy cell leukemia 40 trials Sub-types →
-
Burkitt lymphoma 220 trials
2 sub-types
- Colon Burkitt lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
-
Primary central nervous system lymphoma 92 trials · 103 incl. sub-types
3 sub-types
- Central nervous system non-hodgkin lymphoma 1 trial · 22 incl. sub-types Sub-types →
- Cerebral lymphoma 2 trials
- Spinal cord lymphoma 0 trials
-
MALT lymphoma 30 trials · 31 incl. sub-types
5 sub-types
-
B-cell prolymphocytic leukemia 7 trials
Most studied deeper sub-types
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Phase 1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests an experimental oral drug called UBX-303061 in 94 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or not responded to at least two prior treatments. The main goals are to check safety, find the right dose, a…
Phase 1 • Sponsor: Ubix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for tough blood cancers: experimental drug AC676 enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like leukemia or lymphoma) that returned or didn't respond to prior treatments. The main goals are to find a safe dose and understand side effects. Researchers will also check how …
Phase 1 • Sponsor: Accutar Biotechnology Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test may predict cure and detect resistance in B-Cell cancers
Diagnosis Recruiting nowThis study is testing whether a blood test that looks for tumor DNA in the bloodstream (called a liquid biopsy) can help doctors manage patients with mature B-cell tumors. The goal is to see if the test can accurately predict who is cured after treatment and identify early signs …
Sponsor: Oncology Institute of Southern Switzerland • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC